secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2023-03-03T23:59:59+00:00
Accession:  0001558370-23-002744
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kala enrolls first patient in PCED trial, closes $31M private placement
-----------------------------------------------------------------------

- Enrolled first patient in CHASE Phase 2b trial of KPI-012 for persistent corneal epithelial defect; top-line data targeted for Q1 2024.
- Closed $31.0M private placement in December 2022, extending cash runway into Q1 2025.
- Completed sale of EYSUVIS and INVELTYS to Alcon in Q3 2022 to focus on rare eye diseases.
- Reported Q4 and FY2022 financial results; specific figures not available in the provided excerpt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023002744/0001558370-23-002744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023002744/kala-20230303x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-002744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer